Depatuxizumab mafodotin for recurrent EGFR-amplified glioblastoma multiforme

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Depatuxizumab mafodotin is a new drug to treat a type of brain cancer called recurrent EGFR-amplified glioblastoma multiforme. Glioblastoma is the most common type of brain cancer and develops from cells that support the nerve tissue. Depatuxizumab mafodotin may offer a new treatment option for patients with recurrent EGFR-amplified glioblastoma multiforme whose first treatment has failed and may improve survival when other drugs have failed to work.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/depatuxizumab-mafodotin-for-recurrent-egfr-amplified-glioblastoma-multiforme/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Brain Neoplasms; Glioblastoma; Receptor, Epidermal Growth Factor

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research & Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

Accession Number
32016001027

Date abstract record published
11/10/2016